CHICAGO – Loxo Oncology Inc.'s announcement that it will seek tissue-agnostic approval for larotrectinib (LOXO-101) based on data that were presented at this year's ASCO meeting came just weeks after Keytruda (pembrolizumab, Merck & Co. Inc.) was approved for use in MSI-H/dMMR tumors regardless of tumor histology.